Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixekizumab - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Ixekizumab - Eli Lilly and Company

Alternative Names: LY-2439821; Taltz

Latest Information Update: 30 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly; Eli Lilly and Company; Oregon Health & Science University; Torii Pharmaceutical
  • Class Anti-inflammatories; Antibodies; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Erythrodermic psoriasis; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Phase III Juvenile rheumatoid arthritis
  • Phase II Bullous pemphigoid; Pityriasis rubra pilaris; Pyoderma gangrenosum; Varicose ulcer
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 30 Sep 2024 Eli Lilly and Company plans phase III TOGETHER-PsO trial in Plaque psoriasis and Obesity in US (SC) (NCT06588283)
  • 19 Sep 2024 Eli Lilly and Company plans a phase III TOGETHER-PsA trial for Psoriatic arthritis and Obesity (Monotherapy, Combination therapy) in USA (SC) (NCT06588296)
  • 12 Jun 2024 Phase-III clinical trials in Juvenile rheumatoid arthritis (In adolescents, In children) (SC), before June 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top